1. Home
  2. AKBA vs ASTE Comparison

AKBA vs ASTE Comparison

Compare AKBA & ASTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • ASTE
  • Stock Information
  • Founded
  • AKBA 2007
  • ASTE 1972
  • Country
  • AKBA United States
  • ASTE United States
  • Employees
  • AKBA N/A
  • ASTE N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • ASTE Construction/Ag Equipment/Trucks
  • Sector
  • AKBA Health Care
  • ASTE Industrials
  • Exchange
  • AKBA Nasdaq
  • ASTE Nasdaq
  • Market Cap
  • AKBA 861.7M
  • ASTE 915.1M
  • IPO Year
  • AKBA 2014
  • ASTE N/A
  • Fundamental
  • Price
  • AKBA $3.04
  • ASTE $45.08
  • Analyst Decision
  • AKBA Strong Buy
  • ASTE Hold
  • Analyst Count
  • AKBA 5
  • ASTE 1
  • Target Price
  • AKBA $6.90
  • ASTE $41.00
  • AVG Volume (30 Days)
  • AKBA 4.0M
  • ASTE 192.5K
  • Earning Date
  • AKBA 08-07-2025
  • ASTE 08-06-2025
  • Dividend Yield
  • AKBA N/A
  • ASTE 1.14%
  • EPS Growth
  • AKBA N/A
  • ASTE N/A
  • EPS
  • AKBA N/A
  • ASTE 2.01
  • Revenue
  • AKBA $203,733,000.00
  • ASTE $1,310,100,000.00
  • Revenue This Year
  • AKBA $27.95
  • ASTE $5.43
  • Revenue Next Year
  • AKBA $43.88
  • ASTE $4.22
  • P/E Ratio
  • AKBA N/A
  • ASTE $22.69
  • Revenue Growth
  • AKBA 16.75
  • ASTE 1.17
  • 52 Week Low
  • AKBA $1.24
  • ASTE $29.04
  • 52 Week High
  • AKBA $4.08
  • ASTE $46.64
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 34.84
  • ASTE 62.90
  • Support Level
  • AKBA $2.92
  • ASTE $44.73
  • Resistance Level
  • AKBA $3.44
  • ASTE $46.08
  • Average True Range (ATR)
  • AKBA 0.15
  • ASTE 2.01
  • MACD
  • AKBA -0.06
  • ASTE 0.49
  • Stochastic Oscillator
  • AKBA 13.79
  • ASTE 82.19

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About ASTE Astec Industries Inc.

Astec Industries Inc designs and manufactures equipment and components used in road construction and other development activities. Its products are used through the entire process of building roads, from mining and crushing materials to creating the road surface. The company manufactures a line of plants, pavers, vehicles, and machines to mix and transform materials into construction components. It has two operating segments: infrastructure solutions generating maximum revenue and materials solutions. The majority of sales are derived from the United States. Its customers are asphalt producers, highway and heavy equipment contractors, ready mix concrete producers, demolition recycling markets, sand and gravel producers, open mine operators, quarry operators, and others.

Share on Social Networks: